U
HZNP

UBS’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

UBS’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$25K Buy
2,000
+400
+25% +$4.65K ﹤0.01% 7730
2014
Q2 		$25K Buy
1,600
+600
+60% +$8.56K ﹤0.01% 7813
2014
Q1 		$15K Hold
1,000
– – ﹤0.01% 8476
2013
Q4 		$8K Sell
1,000
-2,000
-67% -$10.8K ﹤0.01% 9225
2013
Q3 		$10K Sell
3,000
-1,800
-38% -$4.75K ﹤0.01% 8842
2013
Q2 		$12K Buy
+4,800
New +$11.5K ﹤0.01% 8475

Other funds holding HZNP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
MRM
Michael R. Murphy $255M AUM 0.87% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS's HZNP Position: Q3 2014 in Review

UBS reduced its Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) stake by 5.8% in Q3 2014, selling an estimated $132K and leaving 182,733 shares worth $2.24M. The position accounts for ﹤0.01% of the portfolio, ranked #2801.

UBS first reported a position in HZNP in Q2 2013 and has held it in 6 quarters since. The position peaked at $3.07M in Q2 2014. 120 funds tracked by Wall St. Rank hold HZNP as of Q3 2014.

  • UBS held 182,733 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $2.24M as of Q3 2014.
  • UBS sold 11,336 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2014, an estimated $132K.
  • Horizon Therapeutics Public Limited Company Ordinary Shares made up ﹤0.01% of UBS's portfolio in Q3 2014, its #2801 holding.
  • UBS first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2013 and has held it in 6 quarters since.
  • UBS's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $3.07M in Q2 2014.
  • 120 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.